

| Numéro de catalogue | MV275012 |
|---|---|
| Description |
Recombinant Mouse PCSK9 Protein, N-His (MV275012) expressed in E. coli. Purity: >90% as determined by SDS-PAGE..
Highlights
|
| Système d'expression | E. coli |
| Numéro d'accès | Q80W65 |
| Longueur de protéine | Gly456-Gln694 |
| Applications | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| Espèces | Mus musculus (Mouse) |
| Nature | Recombinant |
| Cible | EC:3.4.21.-, NARC-1, NARC1, Neural apoptosis-regulated convertase 1, PC9, PCSK9, Proprotein convertase 9, Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9 |
| Niveau d'endotoxines | Please contact with the lab for this information. |
| Pureté | >90% as determined by SDS-PAGE. |
| Masse moléculaire prédite | 27.69 kDa |
| Forme | Lyophilized |
| Tampon de stockage | Lyophilized from a solution in PBS pH 7.4, 1 mM EDTA, 4% Trehalose, 1% Mannitol. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot. |
| Reconstitution | Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details. |
| Expédition | In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise. |
| Stabilité et stockage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Noms alternatifs | EC:3.4.21.-, NARC-1, NARC1, Neural apoptosis-regulated convertase 1, PC9, PCSK9, Proprotein convertase 9, Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9 |
| Contexte | Proprotein convertase subtilisin/kexin type 9 is a ~74 kDa protein. Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. |
| Note | For research use only |
Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.
Courrier : [email protected]
+86-027-65523339
Bâtiment C, No. 666, Rue Shendunsi, Wuhan, 430206, Chine
中文
English
한국어
日本語
Español
Français
Русский